Financials
Financial year 2025
Eurotranspharma Belgium from Aalst, company number BE0541617712, closed financial year 2025 with a result of € 471,104 after tax. For that financial year Eurotranspharma Belgium recorded revenue of € 27 million and equity of € 784,198. Compared with financial year 2024, the result moved from € 28,815 to € 471,104. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.
€ 784,198
▲ 150% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 471,104
▲ € 442,289 vs 2024
Profit after tax over the fiscal year.
€ 1.3 million
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -1,352.
People and assets in 2025
131.8
▼ 4.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 9.1 million
▲ 2% vs 2024
€ 69,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 69,471
▼ 47% vs 2024
Of which on lease € 11,292.
Debts at end 2025
€ 3.7 million
▼ 23% vs 2024
€ 535,071 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 3.3 million
▼ 47% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 62 days on average.
€ 1.4 million
▲ 31% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 24,138,256 | € 26,317,811 | € 26,671,125 | € 27,039,656 | ▲ 1% |
| Profit after taxes | € 198,379 | € 56,522 | € 28,815 | € 471,104 | ▲ € 442,289 |
| Equity | € 227,757 | € 284,279 | € 313,094 | € 784,198 | ▲ 150% |
| Total debts | € 11,912,786 | € 10,155,609 | € 12,088,958 | € 8,406,239 | ▼ 30% |
| Cash | € 1,685,802 | € 758,852 | € 1,164,091 | € 1,334,231 | ▲ 15% |
| Land & buildings | € 20,936 | € 99,511 | € 110,296 | € 97,228 | ▼ 12% |
| Retained profit | € -557,793 | € -501,271 | € -472,456 | € -1,352 | ▲ € 471,104 |
| Bank debt | € 4,940,487 | € 4,800,131 | € 4,771,343 | € 3,682,100 | ▼ 23% |
| Balance sheet total | € 12,140,544 | € 10,439,888 | € 12,402,052 | € 9,190,436 | ▼ 26% |
| Employees (FTE) | 118.8 | 130.8 | 136.3 | 131.8 | ▼ 4.5 |
By revenue, Eurotranspharma Belgium ranks 1st of 5 companies with main activity “Goederenvervoer over de weg” in Aalst that publish figures (fiscal year 2025).
Key figures of Eurotranspharma Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Eurotranspharma Belgium the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Eurotranspharma Belgium?
What happened at Eurotranspharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 471,104 (▲ € 442,289 vs 2024). Source: NBB ↗
- Business Promotion and Management sprl stepped down as director. NBB
- New establishment in Aalst. KBO
- Capital increase of € 150,000, published in the Gazette. Source: Staatsblad ↗
- Business Promotion and Management sprl became a director. NBB
- Capital increase of € 300,000, published in the Gazette. Source: Staatsblad ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in La Louvière. KBO
In short
From € 198,379 profit in 2022 to € 471,104 profit in 2025.
Paid € 14,699 in corporate taxes since 2022.
Best year ever: 2025, with € 471,104 profit.
Pays suppliers within 62 days on average.
Management
The shares are held by Movianto International BV.
Directors
According to the 2025 annual accounts
Business Promotion and Management sprl
Director · represented by Benoît Latteur
since 2018 · until 2026
Shareholders
Movianto International BV
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Waterkeringstraat 1
9320 Aalst
Chemin de la Reconversion(H-G) 91
7110 La Louvière
Active since 25 October 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Aalst
Same main activity (Goederenvervoer over de weg), 24 active companies in Aalst, largest first.
€ 16.3 million revenue · 2024
€ 2.3 million gross margin · 2025
€ 1.7 million gross margin · 2025
€ 474,219 gross margin · 2025
€ 377,477 gross margin · 2025
€ 355,147 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- European Healthcare Distribution Holding(associé unique) 100%
Details
- Company number
- 0541.617.712
- VAT number
- BE 0541.617.712
- Registered office
- Waterkeringstraat 1, 9320 Aalst
- Names & denominations
- Eurotranspharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 November 2013
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Goederenvervoer over de weg
Andere vervoerondersteunende activiteiten
Opslag
Logistieke diensten